Video
Dr. Feldman on Lenvatinib and Pembrolizumab Plus Chemotherapy in NSCLC
Author(s):
Lawrence E. Feldman, MD, discusses the phase 3 LEAP-006 trial evaluating lenvatinib and pembrolizumab plus chemotherapy in non–small cell lung cancer.
Lawrence E. Feldman, MD, medical oncologist, professor of Medicine, the University of Illinois Cancer Center, discusses the phase 3 LEAP-006 trial (NCT03829319) evaluating lenvatinib (Lenvima) and pembrolizumab (Keytruda) plus chemotherapy in non–small cell lung cancer (NSCLC).
The global, randomized, double-blind, placebo-controlled, 2-part trial is evaluating pembrolizumab plus platinum-based chemotherapy, with or without lenvatinib, in patients with previously untreated metastatic nonsquamous NSCLC. Part 1 featured the safety run-in portion of the trial, and the ongoing part 2 is randomized, double-blind portion of the reaserch.
Data from part 1 of LEAP-006 showed that lenvatinib and pembrolizumab plus chemotherapy was well tolerated, Feldman says. Positive safety data were reported, with less than 3 dose-limiting toxicities occurring in each of the 2 arms of the study, Feldman explains.
The findings on safety and tolerability led to the opening of enrollment part 2 of the study in October 2021. With the part 2 primary end points of progression-free survival and overall survival, investigators will look for some of the antitumor activity observed in part 1 of the trial, Feldman concludes.
